Artwork

Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

03_01 The era of immune checkpoint inhibitors

22:59
 
Bagikan
 

Manage episode 359156863 series 3335024
Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

1. History of Immunotherapy
2. Modern immune checkpoint inhibitors (ICIs)
3. Unique considerations with ICIs
4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

45 episode

Artwork
iconBagikan
 
Manage episode 359156863 series 3335024
Konten disediakan oleh Talking About Tumors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Talking About Tumors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

1. History of Immunotherapy
2. Modern immune checkpoint inhibitors (ICIs)
3. Unique considerations with ICIs
4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

45 episode

Todos los episodios

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat